Compare OLED & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLED | ADMA |
|---|---|---|
| Founded | 1985 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 4.7B |
| IPO Year | 1992 | N/A |
| Metric | OLED | ADMA |
|---|---|---|
| Price | $124.50 | $17.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $177.60 | $28.50 |
| AVG Volume (30 Days) | 502.0K | ★ 2.2M |
| Earning Date | 02-19-2026 | 03-02-2026 |
| Dividend Yield | ★ 1.43% | N/A |
| EPS Growth | N/A | ★ 205.35 |
| EPS | ★ 4.64 | 0.86 |
| Revenue | ★ $639,977,000.00 | $488,559,000.00 |
| Revenue This Year | $2.50 | $22.19 |
| Revenue Next Year | $10.90 | $23.71 |
| P/E Ratio | $27.15 | ★ $20.95 |
| Revenue Growth | N/A | ★ 27.63 |
| 52 Week Low | $103.70 | $13.50 |
| 52 Week High | $164.29 | $25.67 |
| Indicator | OLED | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 55.48 | 40.28 |
| Support Level | $121.83 | $16.24 |
| Resistance Level | $126.60 | $18.95 |
| Average True Range (ATR) | 2.69 | 0.70 |
| MACD | 0.93 | -0.22 |
| Stochastic Oscillator | 63.01 | 37.22 |
Universal Display Corp researches, develops, and manufactures organic light-emitting diode, or OLED, technologies for use in displays for mobile phones, tablets, televisions, wearables, personal computers, automotive interiors, and the solid-state lighting market. OLED technologies are an alternative to light-emitting diode, or LED, technologies, in the solid-state lighting market, and liquid crystal displays in the flat-panel-display market. The Company has one reportable business segment being OLED technologies and materials. A large majority of the firm's revenue is generated in South Korea, with the rest coming from Japan, China, the United States, and other countries across the world.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.